E

Endo International PLC
LSE:0Y5F

Watchlist Manager
Endo International PLC
LSE:0Y5F
Watchlist
Price: 888.61 USD 1.47% Market Closed
Market Cap: 199.4B USD

EV/EBITDA
Enterprise Value to EBITDA

331.1
Current
237.6
Median
13
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
331.1
=
Enterprise Value
215.7B USD
/
EBITDA
651.4m USD
All Countries
Close
Market Cap EV/EBITDA
IE
Endo International PLC
LSE:0Y5F
209B USD 331.1
US
Eli Lilly and Co
NYSE:LLY
967.3B USD 35.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
US
Johnson & Johnson
NYSE:JNJ
508B USD 16.5
CH
Roche Holding AG
SIX:ROG
252.3B CHF 11.4
UK
AstraZeneca PLC
LSE:AZN
208.5B GBP 108.3
CH
Novartis AG
SIX:NOVN
202.4B CHF 11.3
US
Merck & Co Inc
NYSE:MRK
247.7B USD 9.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 9.6
US
Pfizer Inc
NYSE:PFE
146.6B USD 7.6
FR
Sanofi SA
PAR:SAN
101.4B EUR 6.7
EBITDA Growth EV/EBITDA to Growth
IE
E
Endo International PLC
LSE:0Y5F
Average EV/EBITDA: 399.4
331.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.2
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.5
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.4
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
11.3
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.3
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
2%
4.8
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
FR
Sanofi SA
PAR:SAN
6.7
8%
0.8

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A